Polyvinyl Alcohol
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Polyvinyl Alcohol: Congenital ichthyosiform erythroderma
One-Sentence Summary
Polyvinyl alcohol is a lubricating polymer originally used in eye drops to treat dry eye syndrome (xerophthalmia). The TxGNN model predicts it may be effective for Congenital Ichthyosiform Erythroderma, but there are currently 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Congenital ichthyosiform erythroderma |
| TxGNN Prediction Score | 0.9990 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (16 of 16) – CDSCO approval status is not included in this data |
| Number of Listed Products | 16 (valid: 16) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, polyvinyl alcohol is a film-forming, water-retaining polymer used as an ocular lubricant. Its efficacy in dry eye comes from stabilising the tear film and retaining moisture on the surface of the eye.
A plausible but unverified link is that the same film-forming and hydrating behaviour could act as a topical occlusive or emollient on skin. This could temporarily improve hydration in scaling disorders and reduce water loss through the skin.
This link is weak. Congenital ichthyosiform erythroderma is a genetic keratinisation disorder, and a moisturising film would at best relieve symptoms rather than treat the underlying disease. The drug’s established use is ocular, not dermatological.
Other predictions from the model follow the same pattern, all with no supporting studies:
| Predicted Indication | TxGNN Score | Evidence Level |
|---|---|---|
| Congenital ichthyosiform erythroderma | 0.9990 | L5 |
| Self-healing collodion baby | 0.9983 | L5 |
| Lamellar ichthyosis | 0.9972 | L5 |
| Bathing suit ichthyosis | 0.9954 | L5 |
For self-healing collodion baby, the condition resolves on its own, and the safety of topical polyvinyl alcohol on a newborn’s compromised skin (where absorption through the skin is higher) has not been assessed.
India Market Information
All 16 licences are for valid products, with none cancelled. The five main ones are listed below. Approved indication text is not recorded in the data compiled for this report.
Review correction (2026-11-06): Originally stated: “All 16 licences are for single-ingredient, valid products, with none cancelled.” Removed: it described the products as single-ingredient or combination products in a way that did not match the Indian medicine data (the Indian Medicine Dataset as of 2026-11-06). Source: Indian Medicine Dataset.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 208557 | Stemoist Eye Drop | Bottle of 10 ml eye drop | Not recorded |
| 218938 | T Plus Eye Drop | Bottle of 5 ml eye drop | Not recorded |
| 105531 | Hypotears 1%/1% Eye Drop | Packet of 10 ml eye drop | Not recorded |
| 123568 | Lentisol Eye Drops | Packet of 10 ml ophthalmic solution | Not recorded |
| 7538 | Aurolube Eye Drop | Bottle of 5 ml eye drop | Not recorded |
All marketed forms are ophthalmic. No topical skin formulation is registered, so the proposed dermatological use would need a new formulation and route.
Safety Considerations
Safety signals from the knowledge graph (these are model-derived relationships, not package insert text) list conditions where the drug may be a concern:
- Cardiovascular: hypertension, hypertensive disorder, heart disease, cardiovascular disease, coronary artery disease, sudden cardiac arrest, heart conduction disease, arteriosclerosis, atherosclerosis
- Metabolic and endocrine: diabetes mellitus, diabetic ketoacidosis, hyperthyroidism, Graves disease, thyrotoxicosis
- Eye: angle-closure glaucoma, closed-angle glaucoma
- Urological: benign prostatic hyperplasia
These graph-derived flags are unusual for a simple lubricant and should be checked against the actual product labelling before being relied on. No drug interaction records were found.
Please refer to the package insert for further safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the TxGNN model score (Evidence Level L5), with no clinical trials or publications. The proposed mechanism is indirect and symptomatic, and the drug is only registered as an eye drop in India.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Indian licences, which are currently missing and block safety screening
- Mechanism of action data for polyvinyl alcohol
- A literature and trial search specifically on topical polyvinyl alcohol or similar film-forming polymers in ichthyosis
- A feasibility assessment of a topical skin formulation and its safety, especially for neonates with impaired skin barrier
- Clarification of the knowledge-graph contraindication flags against actual label information
Review Log
Below is the review log for this page: statements checked against official Indian medicine data (the Indian Medicine Dataset used by this site). Corrections are limited to basic factual statements; model predictions, evidence levels, and conclusions were not rewritten.
| Review date | Item | Action | Source |
|---|---|---|---|
| 2026-11-06 | Removed: “single-ingredient” | Corrected | Indian Medicine Dataset |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.